In quest to beat COVID-19, Bay Area biotech closes Big Pharma equity deal for $250M
April 06, 2020 at 10:31 AM EDT
The companies hope to push two antibodies into mid-stage clinical trials within three to five months.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.